MX2017016806A - Formulaciones farmaceuticas que comprenden tenofovir y emtricitabina. - Google Patents

Formulaciones farmaceuticas que comprenden tenofovir y emtricitabina.

Info

Publication number
MX2017016806A
MX2017016806A MX2017016806A MX2017016806A MX2017016806A MX 2017016806 A MX2017016806 A MX 2017016806A MX 2017016806 A MX2017016806 A MX 2017016806A MX 2017016806 A MX2017016806 A MX 2017016806A MX 2017016806 A MX2017016806 A MX 2017016806A
Authority
MX
Mexico
Prior art keywords
emtricitabine
tenofovir
pharmaceutical formulations
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
MX2017016806A
Other languages
English (en)
Inventor
M Koziara Joanna
Mccallister Scott
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56418608&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017016806(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of MX2017016806A publication Critical patent/MX2017016806A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

La invención proporciona una forma de dosificación oral sólida que comprende tenofovir alafenamida o una sal farmacéuticamente aceptable del mismo, y emtricitabina o una sal farmacéuticamente aceptable de la misma.
MX2017016806A 2015-06-30 2016-06-29 Formulaciones farmaceuticas que comprenden tenofovir y emtricitabina. MX2017016806A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562187113P 2015-06-30 2015-06-30
US201662298373P 2016-02-22 2016-02-22
US201662301429P 2016-02-29 2016-02-29
US201662317286P 2016-04-01 2016-04-01
PCT/US2016/040158 WO2017004244A1 (en) 2015-06-30 2016-06-29 Pharmaceutical formulations comprising tenofovir and emtricitabine

Publications (1)

Publication Number Publication Date
MX2017016806A true MX2017016806A (es) 2018-05-07

Family

ID=56418608

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017016806A MX2017016806A (es) 2015-06-30 2016-06-29 Formulaciones farmaceuticas que comprenden tenofovir y emtricitabina.

Country Status (26)

Country Link
US (2) US20170000807A1 (es)
EP (5) EP4070788B1 (es)
JP (3) JP6667556B2 (es)
KR (2) KR102313668B1 (es)
CN (1) CN107847450A (es)
AU (3) AU2016287500B2 (es)
BR (1) BR112017027843A2 (es)
CA (1) CA2990210C (es)
CL (1) CL2017003320A1 (es)
CO (1) CO2017013293A2 (es)
CU (1) CU20170168A7 (es)
DO (1) DOP2017000306A (es)
EA (1) EA201792592A1 (es)
EC (1) ECSP17084331A (es)
ES (4) ES2786549T3 (es)
HK (1) HK1248547A1 (es)
IL (1) IL256364A (es)
MA (1) MA50541A (es)
MX (1) MX2017016806A (es)
PE (1) PE20180411A1 (es)
PH (1) PH12017502431A1 (es)
PL (4) PL4070788T3 (es)
PT (4) PT3607939T (es)
SI (4) SI4070788T1 (es)
SV (1) SV2017005601A (es)
WO (1) WO2017004244A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3012242C (en) 2012-12-21 2021-11-02 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
SG11201705069YA (en) 2014-12-26 2017-07-28 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto
EP3632415A1 (en) 2015-11-09 2020-04-08 Gilead Sciences, Inc. Therapeutic compositions for treatment of human immunodeficiency virus
EA201991921A1 (ru) 2017-02-17 2020-02-06 Эйдос Терапьютикс, Инк. Способы получения ag-10, его промежуточных соединений и их солей
WO2018153977A1 (en) * 2017-02-24 2018-08-30 Hexal Ag Stable composition of tenofovir alafenamide
EP3600332B1 (en) * 2017-03-20 2023-12-13 The United States of America, as represented by the Secretary, Department of Health and Human Services Hiv post-exposure prophylaxis
RU2662160C9 (ru) * 2017-07-03 2018-10-22 Александрович Иващенко Андрей Комбинированный лекарственный препарат для терапии вирусных инфекций
EP3706762A4 (en) 2017-12-07 2021-09-01 Emory University N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTIVIRAL USES IN RELATION TO IT
EA202190561A1 (ru) * 2018-08-17 2021-05-26 Эйдос Терапьютикс, Инк. Препараты ag10
CN111096954B (zh) * 2018-10-29 2022-09-16 江苏豪森药业集团有限公司 一种用于抗病毒感染的药物组合物及制备方法
CN110251476B (zh) * 2019-08-01 2022-08-09 海思科制药(眉山)有限公司 一种恩曲他滨替诺福韦药物组合物
CN110917197A (zh) * 2019-12-31 2020-03-27 常州恒邦药业有限公司 一种替诺福韦酯与恩曲他滨的药物组合物及其制备方法
TWI728709B (zh) * 2020-02-19 2021-05-21 台灣森本生物科技開發股份有限公司 含有得自於藤黃樹脂的丙酮萃取產物的藥學組成物以及由該組成物所製得的配方

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20160074B1 (hr) 2000-07-21 2021-09-03 Gilead Sciences, Inc. Prolijekovi koji su fosfonatni analozi nukleotida i metode njihovog odabira te njihova priprava
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
EP3025718A1 (en) * 2003-01-14 2016-06-01 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
TWI471145B (zh) * 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
PE20110994A1 (es) 2009-02-06 2012-01-24 Gilead Sciences Inc Comprimidos antivirales que comprenden elvitegravir, emtricitabina, disoproxil fumarato de tenofovir y un derivado de tiazol
UA115311C2 (uk) 2011-08-16 2017-10-25 Гіліад Сайєнсіз, Інк. Геміфумарат тенофовіру алафенаміду
BR112014018918A8 (pt) * 2012-02-03 2017-07-11 Gilead Sciences Inc Terapia de combinação compreendendo hemifumarato de tenofovir alafenamida e cobicistato para uso no tratamento de infecções virais
EA201690146A1 (ru) * 2013-08-14 2016-07-29 Ратиофарм Гмбх Лекарственное средство, содержащее фармацевтическую комбинацию долутегравира, эмтрицитабина и тенофовира
CZ2013985A3 (cs) * 2013-12-09 2015-06-17 Zentiva, K.S. Stabilní farmaceutická kompozice obsahující tenofovir disoproxil fumarát
NO2717902T3 (es) * 2014-06-20 2018-06-23

Also Published As

Publication number Publication date
CU20170168A7 (es) 2018-07-05
JP2021185188A (ja) 2021-12-09
EP3607939A1 (en) 2020-02-12
SI4070788T1 (sl) 2023-06-30
SV2017005601A (es) 2018-05-04
JP2018519297A (ja) 2018-07-19
KR20200067937A (ko) 2020-06-12
EP4233846A2 (en) 2023-08-30
ES2925246T3 (es) 2022-10-14
CN107847450A (zh) 2018-03-27
DOP2017000306A (es) 2018-01-15
PL3607939T3 (pl) 2022-11-07
EP4070788B1 (en) 2023-03-22
EP4233846A3 (en) 2023-10-04
KR102121329B1 (ko) 2020-06-17
KR102313668B1 (ko) 2021-10-19
JP6667556B2 (ja) 2020-03-18
AU2021202009B2 (en) 2023-04-13
WO2017004244A1 (en) 2017-01-05
JP2020079304A (ja) 2020-05-28
PT4070788T (pt) 2023-06-06
ES2786549T3 (es) 2020-10-13
PT3607939T (pt) 2022-09-12
ES2945345T3 (es) 2023-06-30
PL4070788T3 (pl) 2023-07-10
SI4070787T1 (sl) 2023-07-31
PL3316868T3 (pl) 2020-10-19
PL4070787T3 (pl) 2023-07-24
PE20180411A1 (es) 2018-03-01
EA201792592A1 (ru) 2018-06-29
AU2021202009A1 (en) 2021-04-29
SI3607939T1 (sl) 2022-10-28
ECSP17084331A (es) 2018-01-31
CO2017013293A2 (es) 2018-05-31
CA2990210A1 (en) 2017-01-05
EP3607939B1 (en) 2022-06-01
SI3316868T1 (sl) 2020-04-30
US20180177734A1 (en) 2018-06-28
AU2019210558B2 (en) 2021-04-22
AU2019210558A1 (en) 2019-08-15
IL256364A (en) 2018-02-28
EP4070787B1 (en) 2023-03-01
ES2945896T3 (es) 2023-07-10
HK1248547A1 (zh) 2018-10-19
BR112017027843A2 (pt) 2018-09-04
EP4070788A1 (en) 2022-10-12
JP6978534B2 (ja) 2021-12-08
PH12017502431A1 (en) 2018-07-02
EP4070787A1 (en) 2022-10-12
KR20180021134A (ko) 2018-02-28
US20170000807A1 (en) 2017-01-05
CA2990210C (en) 2021-01-12
PT3316868T (pt) 2020-04-21
EP3316868A1 (en) 2018-05-09
MA50541A (fr) 2021-04-07
AU2016287500A1 (en) 2018-01-18
CL2017003320A1 (es) 2018-07-13
PT4070787T (pt) 2023-05-22
EP3316868B1 (en) 2020-02-19
AU2016287500B2 (en) 2019-05-02

Similar Documents

Publication Publication Date Title
PH12017502431A1 (en) Pharmaceutical formulations comprising tenofovir and emtrictabine
MX2017016802A (es) Formulaciones farmaceuticas.
IL258464A (en) Pharmaceutical compositions for oral administration of peptide drugs
IL283134A (en) Formulations of alcohol-resistant drugs
HUP1700253A1 (hu) Szilárd orális gyógyszerkészítmények
PH12016501841A1 (en) Immunosuppressant formulation
IL285674A (en) Pharmaceutical formulations
ZA202006570B (en) Pharmaceutical formulations
MX2018005358A (es) Comprimido de dosis alta que contiene mesalazina optimizado.
PH12018501758A1 (en) Oritavancin formulations
IL282343A (en) soluble medicinal compounds
PL3326619T3 (pl) Stałe doustne kompozycje farmaceutyczne zawierające tenofowir i emtrycytabinę
IL291283A (en) Formulations for drug delivery
IL282842A (en) Medicinal compounds for subcutaneous control
IL271908A (en) Over-compressed pharmaceutical preparations
SG11202010792TA (en) Improved pharmaceutical formulations
WO2019059868A3 (en) PHARMACEUTICAL COMBINATIONS OF TENOFOVIR, EMTRICITABINE AND EFAVIRENZ
JOP20170198A1 (ar) صيغ صيدلية تشتمل على تينوفوفير و إيمترايسيتابين
EP3723761A4 (en) SOLID ORAL DOSAGE FORM WITH LINAGLIPTIN
EP3697393A4 (en) PHARMACEUTICAL DOSAGE FORMS
CR20170601A (es) Formulaciones farmaceuticas que comprenden tenofovir y emtricitabina
IN2013MU03370A (es)
TR201721065A2 (tr) Deksmedetomi̇di̇n i̇çeren li̇yofi̇li̇ze farmasöti̇k formülasyonlar
EP3634507A4 (en) PROLONGED ORAL DRUG DELIVERY PLATFORMS
EP3675842A4 (en) PHARMACEUTICAL DOSAGE FORMS